Form 4: Glaukos CDO Sells Shares Under 10b5-1 Plan

Glaukos Corp's Chief Development Officer, Tomas Navratil, reported sales of common stock totaling 1,031 shares and tax-related dispositions of 958 shares on March 16, 2026, under a pre-arranged trading plan.

Summary

• Tomas Navratil, Chief Development Officer of Glaukos Corp (GKOS), reported transactions on March 16, 2026.
• Disposed of 958 shares of common stock at $98.94 for tax withholding obligations related to restricted stock units previously granted on March 14, 2024.
• Sold a total of 1,031 shares of common stock in three separate transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026.
• The sales occurred at weighted average prices of $97.33 (460 shares), $98.21 (299 shares), and $99.05 (272 shares).
• Following these transactions, Navratil beneficially owns 73,631 shares of Glaukos common stock, which includes 35,687 unvested restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and personal financial planning, especially given the use of a Rule 10b5-1 plan for sales.

Positives

• Sales were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions rather than opportunistic selling.

Negatives

• Chief Development Officer Tomas Navratil sold a total of 1,031 shares of common stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are a routine part of executive compensation and personal financial management in the medical device and ophthalmology industry. These plans allow executives to sell shares over time without concerns about insider trading allegations.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are standard practice across publicly traded companies, including peers in the medical device sector like Alcon (ALC), Bausch + Lomb (BLCO), and Johnson & Johnson (JNJ) Vision, where executives regularly manage their equity holdings through such pre-arranged programs.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe a slight increase in the public float due to executive sales, but the impact is generally minimal given the volume relative to total outstanding shares. The use of a 10b5-1 plan provides transparency.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically sales under a pre-arranged 10b5-1 plan and tax-related dispositions. Such transactions are common for executives managing their equity compensation and personal finances and do not typically signal a change in the company's fundamental outlook or performance. Therefore, the filing itself does not provide a basis for a change in investment recommendation, suggesting a "hold" position remains appropriate based solely on this disclosure.

Keywords

Glaukos, GKOS, insider trading, Form 4, stock sale, executive compensation, Tomas Navratil, 10b5-1 plan, Chief Development Officer